Clinical Trials Browser

OTHER × olaparib × Genitourinary × Clear all

NCT04748042 2026-03-06

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03263650 2026-02-17

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

Phase 2 Active not recruiting

Prostate Cancer, Hereditary, 7, Prostatic Neoplasms

NCT05568550 2026-01-30

Pembro With Radiation With or Without Olaparib

Phase 2 Recruiting

Prostatic Neoplasms

NCT05498272 2026-01-23

NePtune

Phase 2 Recruiting

Prostatic Neoplasms

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2 Active not recruiting

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT03012321 2025-10-21

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03516812 2025-09-29

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

Phase 2 Completed

36 enrolled 14 charts

Castration-Resistant Prostate Carcinoma

NCT04336943 2025-08-11

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

Phase 2 Terminated

6 enrolled 10 charts

Biochemically Recurrent Prostate Carcinoma

NCT07090369 2025-07-29

LumOnate

Phase 1 Not yet recruiting

Prostatic Neoplasms

NCT03432897 2025-07-08

337

Phase 2 Terminated

1 enrolled 8 charts

Prostatic Neoplasms

NCT03047135 2025-06-17

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

Phase 2 Active not recruiting

51 enrolled 8 charts

Prostate

NCT03874884 2025-05-14

LuPARP

Phase 1 Active not recruiting

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT03787680 2025-03-28

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

Phase 2 Active not recruiting

49 enrolled 11 charts

Prostatic Neoplasms

NCT03786796 2025-03-13

ORCHID

Phase 2 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05501548 2025-01-29

Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer

Phase 2 Terminated

4 enrolled 5 charts

Prostatic Neoplasms

NCT04951492 2025-01-01

Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

Phase 2 Terminated

2 enrolled 9 charts

Castration-Resistant Prostate Carcinoma

NCT03810105 2024-04-09

A Study of Olaparib and Durvalumab in Prostate Cancer

Phase 2 Terminated

5 enrolled 4 charts

Prostatic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT05949424 2023-11-29

OPTI-DOSE

Phase 4 Unknown

BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Carcinoma, Renal Cell, Ovarian Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

NCT03448718 2023-11-22

Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

Phase 2 Completed

19 enrolled 9 charts

Metastatic Urothelial Cancer

NCT03434158 2022-11-03

IMANOL

Phase 2 Completed

Prostate Cancer Metastatic

NCT05167175 2022-10-25

The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation

Phase 2 Unknown

Prostatic Neoplasms

NCT05262608 2022-03-02

PROspect

Phase 2 Unknown

Prostatic Neoplasms

NCT04579133 2021-06-16

Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy

Phase 2 Terminated

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03534492 2020-04-06

NEODURVARIB

Phase 2 Completed

Urinary Bladder Neoplasms

NCT02324998 2019-08-29

CaNCaP03

Phase 1 Completed

Prostatic Neoplasms